Book Review: A Look At Antitrust Issues In Intellectual Property Law 09/01/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment The book Antitrust Issues in Intellectual Property Law, edited by Bradford Lyerla and authored by several lawyers, is about the intersection of IP law and antitrust law and collects case law from 2015 and 20152016??, dealing with the issue.
UN Establishes Technology Bank For Least-Developed Countries, Including An IP Bank 06/01/2017 by William New, Intellectual Property Watch 1 Comment The United Nations has established a “technology bank” for least-developed countries that aims to strengthen the science, technology and innovation capacity of LDCs that includes better management of intellectual property rights.
ARIPO Amends Protocol On Patents, Utility Models And Designs 06/01/2017 by Hillary Muheebwa for Intellectual Property Watch Leave a Comment The Harare Protocol on Patents, Industrial Designs and Utility Models has been amended. The amendments were adopted by the 40th Session of the African Regional Intellectual Property Organization (ARIPO) Administrative Council, and came into operational effect from 1 January 2017.
Top IP-Watch Stories Of 2016 Reflect Cutting Edge Issues, Lingering Concerns 05/01/2017 by William New, Intellectual Property Watch Leave a Comment Hundreds of thousands of people visited articles on Intellectual Property Watch last year, and we published nearly 1,000 original articles. The year’s most-visited articles reflected a mix of new ideas and policies worldwide and some recurring issues, with especially heavy attention on stories involving India.
US Food And Drug Administration Issues Equivalence Guideline For Biosimilars Producers 05/01/2017 by Intellectual Property Watch 1 Comment Biotherapeutic medicines are made out of living organisms and cannot be replicated. No generic medicines, which are exact copies of the reference product, can be made. The generic equivalent of a biotherapeutic would be biosimilars, which are highly similar products. The United States Food and Drug Administration has issued a guide to help producers to prove how close their biosimilars are to the biotherapeutics.
Roundtable: ‘Appropriate Level’ Of Protection Is Key For Impact Of Patents In Health, Innovation 03/01/2017 by Peter Kenny for Intellectual Property Watch Leave a Comment One of the key questions around the impact of patents on health and innovation is what is the appropriate level of protection for companies innovating, says Dr. Marie-Paul Kieny, assistant director-general, Health Systems and Innovation, at the World Health Organization.
IP World Enters New Year With Major Shift Of People In Pharma, Copyright 22/12/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment As a new year dawns, a lot of movement has been observed in the pharmaceutical industry with new key players taking the lead. Meanwhile, new delegates are covering IP issues in Geneva, and coordination of regional groups at the World Intellectual Property Organization makes its usual yearly shift for 2017. The copyright industry also saw major changes, and law offices have been busy hiring new partners.
2016 USTR List Of ‘Notorious’ Markets: Stream Ripping, Taobao And Switzerland 21/12/2016 by William New, Intellectual Property Watch 1 Comment The United States Trade Representative’s office today released its annual “notorious markets” for intellectual property-infringing goods, with a list of 21 online and 12 physical markets worldwide. Many of the online sites are based across Europe, including several in Switzerland, but also in Russia and China as in the past. A big feature is China’s Taobao, and new methods like stream ripping.
US Supreme Court Eyes Patent-Enforced Post-Sale Restrictions 21/12/2016 by Steven Seidenberg for Intellectual Property Watch Leave a Comment Few were surprised when, earlier this month, the US Supreme Court agreed to hear the appeal in Impression Products, Inc. v. Lexmark International. The case presents two important patent law issues, and the lower court’s ruling on these issues conflicts with Supreme Court precedents, according to many experts.
ECJ Advocate General Says EU Commission Cannot Make Trade Deals Without Member States 21/12/2016 by Intellectual Property Watch 1 Comment Not all parts of the European Union-Singapore trade agreement “fall within the EU’s exclusive competence and therefore the agreement cannot be concluded without the participation of all of the Member States.” This is the result of an opinion of the European Court of Justice Advocate General Eleanor Sharpston published today.